BRAF and melanoma: It is worthwhile noting that both vemurafenib and PLX8394 have little to no effect on proliferation, activation of AKT and ERK, induction of apoptosis, migration and invasion, and colony formation- anchorage-independent growth in melanoma cells harboring BRAF class II/III mutations such as C8161, WM3670, and WM3629 cells.